Objective: To investigate the effect of oral administration of type II collagen (CII ) on pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis (AA).
Rheumatoid arthritis (RA) is an autoimmune disease characterized by hyperplasia of synovium with resultant cartilage destruction. Proliferation of the synovium is associated with increased production of pro -inflammatory cytokines, mainly interleukin (IL)-1 and tumour necrosis factor (TNF), which play crucial roles in cartilage degradation [1, 2] . Nitric oxide (NO) and oxygen radials also play an important role in chondrocyte catabolic activity [3] . Therefore, suppression of production of these pro-inflammatory mediators by synovial cells may be an important target of therapy for RA.
Oral tolerance, a state of immunological unresponsiveness induced by oral administration of antigen, has posed intriguing possibilities for the treatment of autoimmune diseases including RA, multiple sclerosis and insulin dependent diabetes [4] [5] [6] [7] [8] . Oral tolerance has been applied to prevent and treat autoimmune disease in several animal models including arthritis. Oral administration of type II collagen (CII) has been shown to suppress collagen [9] [10] [11] , adjuvant [12] , antigen [13] and pristane [14] induced arthritis in mice and rats. However, the precise mechanisms of oral tolerance are not fully known. Studies of experimental autoimmune encephalomyelitis (EAE) have shown that oral toler ance of myelin basic protein (MBP) was associated with down-regulation of pro-inflammatory cytokines such as IL -1 and TNF expressions and up-regulation of suppressive cytokines such as transforming growth factor (TGF)-and IL-4 expressions in brain tissue [15] . It is generally agreed that the regulation of mucosally induced tolerance involves several mechanisms, including active suppression induced by low doses of antigen and clonal anergy or deletion induced by high doses of antigen [4 -8,16] . Cells from Peyer's patches (PP) in the gutassociated lymphoid tissue (GALT) and TGF -are reported to mediate the induction of active suppression [17, 18] . But there are few reports about the mechanisms of mucosal tolerance to CII in animal models of arthritis [11 -13, 19-22] , especially its effect on synoviocytes.
Adjuvant arthritis (AA) is a commonly used model of human RA with an incidence of around 90%, which makes it ideal to investigate anti -inflammatory effects. In the present study, therefore, we tested the effect of oral administration of CII on proinflammatory mediator producti on by synoviocytes in rats with AA. Oral administration of CII In the pre-treatment protocol, rats were fed daily doses of 5, 50 or 500 µg/Kg of bovine CI I (provided by Qilu Pharmaceutical Company, China) dissolved in 0.01 M acetic acid using an 18 -gauge stainless steel animalfeeding needle for 7 days prior to immunization. Control rats were only fed the same volume of vehicle (0.01 M acetic acid). In the treatment protocol, rats were treated orally with above doses of CII or vehicle for 7 days from day 13 after immunization, for paw swelling appeared on day 10 -13.
MATERIALS AND METHODS

Animals
Synovial cell isolation and cultures
Synovial cells (synoviocytes) were isolated as described [23, 24] . After measurement of paw swelling, rats were killed at day 30 after immunization, and the synovial tissue from right ankle was excised. The synovial membranes were minced aseptically, then dissociated enzymatically using collagenase (4.0 mg/ml, Sigma) in Dulbecco's modified Eagle's medium (DMEM, GIBCO) for 4 h at 37 0 C. After centrifugation for 10 minutes at 500 g, cells were resuspended in DMEM with 2 mM L -glutamine, 100 U/ml penicillin, 50 µg/ml gentamicin, 20 nM HEPES buffer, and 10% fetal ca lf serum (FCS). Cells were culture in 50 ml culture dishes in humidified 5% CO 2 atmosphere at 37 0 C. After adherence for 18 h, cells were washed thoroughly with phosphate -buffered saline (PBS) solution. Adherent synovial cells were removed by adding trypsi n-EDTA followed by washing with PBS containing 2% FCS. Synovial cells collected from different groups were used in 4-5 passages for subsequent experiments, when they showed fibroblastoid morphology. They (5×10 5 /well) were cultured for 48 h with 5µg/ml lipopolysaccharide (LPS, Sigma) and the supernatants were collected for measurement.
Serum collection from oral tolerized rats Rats were treated orally with CII 5, 50 or 500 µg/Kg or vehicle daily for 7 days. Two days later, blood samples were obtained from portal vein while rats were under light ether anesthesia. After centrifugation, pooled serum was added to culture medium of synovial cells, and the dilution of 1:10 was found to be most effective on synoviocyte function. 
In vitro experiments
Statistical analysis
Results were expressed as mean ± SD. Student's t -test was used to make comparisons between the groups. P values <0.05 were considered statistically significant.
RESULTS
CII oral pre-treatment suppresses AA and synoviocyte function
To determine if oral administration of CII has prophylactic effect on AA, AA rats were pre-fed with vehicle or three doses of CII for 7 days before immunization. As shown in Table 1 To investigate the effects of pre -feeding with CII on synoviocyte function in AA rats, the rats were decapitated at day 30 a fter immunization and IL-1, TNF, NO and MDA levels produced from synoviocytes were measured. As shown in Table 2 , IL -1, TNF, NO and MDA produced from synoviocytes increased significantly in AA rats as compared with those in normal rats (all P<0.01). Daily pre-feeding of 3 doses of CII had significant inhibitory effects on IL -1, TNF, NO and MDA production from synoviocytes as compared with daily pre -feeding with vehicle (all P<0.01) in AA rats.
The most pronounced effect was seen in the group fed with 50 µ g/Kg of CII.
CII oral treatment suppresses AA and synoviocyte function
To test if oral administration of CII has therapeutical effect on AA, AA rats were fed with vehicle or three doses of CII for 7 days from day 13 after immunization. As shown in Table 3 , daily oral treatment with CII 5, 50 and 500 µg/Kg also significantly suppressed hind paw secondary swelling measured at day 20, 24 and 28 after immunization (all P<0.01). The suppression rates ranged between 20.2% and 35.8%.
To examine the effects of oral treatment with CII on synoviocyte function in AA rats, the rats were decapitated at day 30 after immunization and IL -1, TNF, NO and MDA produced from synoviocytes were measured. As shown in Table 4 , daily feeding of 3 doses of CII had significant i nhibitory effects on IL-1, TNF, NO and MDA production from synoviocytes as compared with daily feeding with vehicle (all P<0.01) in AA rats. The most pronounced effect was also seen in the group fed with 50 µg/Kg of CII.
CII suppresses synoviocyte functi on via PP cells and TGF-in vitro
To test if CII has a direct effect on synoviocytes, in vitro experiments were employed.
As shown in Figure 1 , CII 1, 10, 100 µg/ml had no effects on IL -1 and TNF production by synoviocytes of AA rats in vitro.
As Figure 2 , CII 10 µg/ml had no effect on IL-1 and TNF production from synovi ocytes of AA rats in vitro (group 2 vs group 1, P>0.05). PP cells (10 6 /well) from normal rats also had no effect on IL -1 and TNF production when co-cultured with synoviocytes (5×10 5 /well) from AA rats (group 3 vs group 1, P>0.05). However, CII 10 µg/ml sup pressed IL-1 and TNF production significantly in the co-culture system (group 4 vs group 2 and 3, P<0.01). Meanwhile, anti-TGF-antibody (10 µg/ml) was added and it was demonstrated that anti -TGF-, which had no effect on IL-1 and TNF production by synoviocytes(group 5 vs group 2, P>0.05), significantly antagonised the suppressive effects of CII on IL -1 and TNF production in the co-culture system (group 6 vs group 4, P<0.01).
Serum from oral tolerized rats suppresses synoviocyte function in vitro
To determine if the suppressive effects of oral administration of CII on synoviocyte function are through blood mediators, we collecte d the portal vein sera from the rats fed with CII 5, 50 or 500 µg/Kg or vehicle (as a control) daily for 7 days and tested the effects of these sera on synoviocyte function in vitro. As shown in Figure 3 , as compared with serum (1:10) from rats fed with v ehicle, serum (1:10) from rats fed with CII 5, 50 or 500 µg/Kg significantly inhibited IL -1 and TNF production from synoviocytes of AA rats (all P<0.01).
Furthermore, to test if the inhibitory effects of these sera are via TGFin blood, we added anti-TGF-antibody (10 µg/ml) together with serum from rats fed with CII 50 µg/Kg or vehicle into the synoviocytes culture medium. As shown in Figure 4 , serum (1:10) from rats fed with CII 50 µg/Kg had inhibitory effects on IL -1 and TNF production from synoviocytes of AA rats (group 2 vs group 1, P<0.01), which antagonized by anti-TGF-(group 4 vs group 2, P<0.01).
DISCUSSION
Our study demonstrated that oral CII pre -feeding or feeding suppressed secondary hind paw swelling and pre -inflammatory mediators production in AA. CII had no direct effect on synoviocyte function in vitro, but it could suppress IL-1 and TNF production by synoviocytes via TGFsecrected by PP cells. Furthermore, portal serum from oral tolerized rats suppressed IL -1 and TNF production by synoviocytes via TGF-in vitro.
Beginning with collagen-induced arthritis (CIA) in rats [10] and mice [9] , oral administration of CII has been found to suppress virtually all experimentally inducible animal models that exist for RA [11 -14, 32] . Histopathological studies showed that oral administration of CII resulted in reduction of synovial hyperplasia, mononuclear infiltration, pannus formation, and cartilage erosions [14] . In AA models, using Lewis rats weighing between 125 to 150 grams, da ily doses of 3 or 30 µg of native chicken CII abrogated the disease to a statistically significant degree, whereas higher doses or a dose of 0.3 µg/day were ineffective. Both pre -feeding and feeding suppressed the disease of AA [12] . In our present study, using 150-190 g SD rats, we found that daily oral administration of bovine CII 5, 50 and 500 µg/kg for 7 days either before or after immunization suppressed secondary hind paw swelling of AA. Our results and doses are consistent with the previous findings [12] . Moreover, we demonstrated, for the first time, that oral administration of CII either before or after immunization inhibited the production of pro-inflammatory mediators, i.e., IL -1, TNF, NO and MDA, from synoviocytes in AA. These results suggest th at suppression of paw swelling by oral CII may be through suppression of pro -inflammatory mediator production by synoviocytes. This implies that oral administration of CII could modify the disease activity of arthritis, for these pro -inflammatory mediators play crucial roles in cartilage degradation in inflammatory arthritis [1 -3] . Although the effects of oral administration of CII in the treatment of RA from clinical trials are inconsistent, showing no effect, non significant, or significant improvement in the disease [8, [33] [34] [35] [36] ], our present study in AA supports the concept that OT induction by CII has a potential prospect in modifying disease activity of RA. The roles of PP cells and TGF-in OT were verified by our present in vitro study.
We found that CII (1, 10 and 100 µg/ml) had no direct effect on IL -1 and TNF production by synoviocytes. However, when PP cells were added to the culture system, CII 10 µg/ml significantly inhibited IL -1 and TNF production by synoviocytes. This effect of CII was antagonized by anti -TGF-antibody (10 µg/ml).
Our findings strongly suggest that bystander active suppression is the main mechanism of OT to CII, which is consistent with previous reports [11 -13,19-22] . It has been reported that spleen cells, and nylon wool -filterer splenic T cells from CIIinduced OT rats adoptively transferred hyporesponsiveness to normal recipients that were less susceptible to AA or CIA [12, 19] Surgical approaches using portacaval shunts showed that the development of OT is dependent on the hepatic portal circulation [45, 46] , so we studied the effect of the serum in portal vein from oral tolerized rats. We found that the serum suppressed IL -1
and TNF production by synoviocytes in vitro, which was antagonized by anti -TGFantibody. This result suggests that TGF-level in the hepatic portal circulation may also play a role in suppression of synovial inflammation by oral administration of CII.
In conclusion, oral administration of CII had prophylactic and therapeutic effects on AA and over-production of IL-1, TNF, NO and MDA by synoviocytes was suppressed. CII had no direct effect on synoviocytes, but it could suppress IL - 
